BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

OrBec beclomethasone dipropionate: Phase III started

Soligenix (formerly Dor BioPharma Inc.) began the double-blind, placebo-controlled U.S. Phase III SUPPORTS trial to evaluate oral orBec given twice daily for 50 days. Soligenix has an SPA from FDA for the...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >